42 related articles for article (PubMed ID: 26309122)
1. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.
Abdelkarim H; Neelarapu R; Madriaga A; Vaidya AS; Kastrati I; Karumudi B; Wang YT; Taha TY; Thatcher GRJ; Frasor J; Petukhov PA
ChemMedChem; 2017 Dec; 12(24):2030-2043. PubMed ID: 29080240
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
Sodji QH; Patil V; Kornacki JR; Mrksich M; Oyelere AK
J Med Chem; 2013 Dec; 56(24):9969-81. PubMed ID: 24304348
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
Raji I; Yadudu F; Janeira E; Fathi S; Szymczak L; Kornacki JR; Komatsu K; Li JD; Mrksich M; Oyelere AK
Bioorg Med Chem; 2017 Feb; 25(3):1202-1218. PubMed ID: 28057407
[TBL] [Abstract][Full Text] [Related]
4. Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease.
Cao X; Fan Z; Xu L; Zhao W; Zhang H; Yang Y; Ren Y; Xiao Y; Zhou N; Yin L; Zhou X; Zhu X; Guo D
Eur J Med Chem; 2024 May; 271():116428. PubMed ID: 38653068
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation.
Khadempar S; Lotfi M; Haghiralsadat F; Saidijam M; Ghasemi N; Afshar S
Comput Biol Med; 2023 Nov; 166():107518. PubMed ID: 37806058
[TBL] [Abstract][Full Text] [Related]
6. Leveraging a rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of pH-responsive polymer nanoformulation.
Thakur A; Chu YH; Rao NV; Mathew J; Grewal AS; Prabakaran P; Guru S; Liou JP; Pan CH; Nepali K
Eur J Med Chem; 2024 Jul; 273():116507. PubMed ID: 38776806
[TBL] [Abstract][Full Text] [Related]
7. Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors.
Sun R; Hu Y; Liu X; Lin Y; Lv D; Li W; Fu L; Jiang F
Bioorg Chem; 2024 Jul; 148():107460. PubMed ID: 38781668
[TBL] [Abstract][Full Text] [Related]
8. Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms.
Nepali K; Lee HY; Lai MJ; Ojha R; Wu TY; Wu GX; Chen MC; Liou JP
Eur J Med Chem; 2017 Feb; 127():115-127. PubMed ID: 28038324
[TBL] [Abstract][Full Text] [Related]
9. Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].
Lee JH; Yao Y; Mahendran A; Ngo L; Venta-Perez G; Choy ML; Breslow R; Marks PA
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):12005-10. PubMed ID: 26371309
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Histone Deacetylase 6 Activity via S-Nitrosylation.
Okuda K; Ito A; Uehara T
Biol Pharm Bull; 2015; 38(9):1434-7. PubMed ID: 26328501
[TBL] [Abstract][Full Text] [Related]
11. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
12. HDAC6: A unique HDAC family member as a cancer target.
Kaur S; Rajoria P; Chopra M
Cell Oncol (Dordr); 2022 Oct; 45(5):779-829. PubMed ID: 36036883
[TBL] [Abstract][Full Text] [Related]
13. Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer.
Zhou B; Liu D; Tan Y
Front Cell Dev Biol; 2021; 9():719390. PubMed ID: 34938729
[TBL] [Abstract][Full Text] [Related]
14. HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?
Losson H; Schnekenburger M; Dicato M; Diederich M
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32013157
[TBL] [Abstract][Full Text] [Related]
15. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Lin A; Giuliano CJ; Palladino A; John KM; Abramowicz C; Yuan ML; Sausville EL; Lukow DA; Liu L; Chait AR; Galluzzo ZC; Tucker C; Sheltzer JM
Sci Transl Med; 2019 Sep; 11(509):. PubMed ID: 31511426
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase 6 is overexpressed and promotes tumor growth of colon cancer through regulation of the MAPK/ERK signal pathway.
Zhang SL; Zhu HY; Zhou BY; Chu Y; Huo JR; Tan YY; Liu DL
Onco Targets Ther; 2019; 12():2409-2419. PubMed ID: 31118659
[No Abstract] [Full Text] [Related]
17. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
[TBL] [Abstract][Full Text] [Related]
18. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
